Oscar Health, Inc. (OSCR)
Oscar Health: I'm Bullish, But I'm Careful
Oscar Health is uniquely undervalued, combining 42% revenue growth with profitability and a low EV/Sales multiple, making it a standout in the market. The company's $2.23B cash position versus its $4.8B market cap highlights significant balance sheet strength and downside protection. ICHRA market expansion offers massive upside potential, but regulatory risks and limited pricing power cap long-term sustainability.
Oscar Health (OSCR) Soars 7.8%: Is Further Upside Left in the Stock?
Oscar Health (OSCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Oscar Health Could Be The Next Growth Monster With Tremendous Upside
Oscar Health is leveraging technology and AI to disrupt the health insurance industry, driving strong membership growth and improving operational efficiency. Financials are rapidly improving: premium revenue growth outpaces claims, margins are expanding, and the company has turned profitable with a strong balance sheet. Analysts project massive EPS growth through 2027, making OSCR undervalued compared to peers and offering significant upside for risk-tolerant investors.
Oscar Health, Inc. (OSCR) Laps the Stock Market: Here's Why
Oscar Health, Inc. (OSCR) reached $14.34 at the closing of the latest trading day, reflecting a +1.34% change compared to its last close.
Oscar Health: Steep Budget Cuts In 2026 Healthcare Estimates Spell Uncertainty
I rate Oscar Health as a Hold, due to proposed steep budget cuts in the 2026 budget, impacting Medicaid and Medicare Advantage coverage. Oscar Health's impressive financials and revenue growth are overshadowed by macroeconomic risks, including potential policy changes and increased uninsured rates. Despite strong internal operations and a projected revenue CAGR of ~20% between 2024 and 2027, external factors pose significant risks to growth.
Oscar Health, Inc. (OSCR) Q1 2025 Earnings Call Transcript
Oscar Health, Inc. (NYSE:OSCR ) Q1 2025 Earnings Conference Call May 7, 2025 8:00 AM ET Company Participants Chris Potochar - Vice President of Treasury and Investor Relations Mark Bertolini - Chief Executive Officer Scott Blackley - Chief Financial Officer Conference Call Participants John Ransom - Raymond James Stephen Baxter - Wells Fargo Jonathan Yong - UBS Joanna Gajuk - Bank of America Josh Raskin - Nephron Research Jessica Tassan - Piper Sandler Michael Ha - Baird David Windley - Jefferies Operator Good morning, everyone. My name is Ellie, and I will be your conference operator for today.
Oscar Health, Inc. (OSCR) Beats Q1 Earnings and Revenue Estimates
Oscar Health, Inc. (OSCR) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.83 per share. This compares to earnings of $0.62 per share a year ago.
Oscar Health, Inc. (OSCR) Stock Declines While Market Improves: Some Information for Investors
In the closing of the recent trading day, Oscar Health, Inc. (OSCR) stood at $13.01, denoting a -1.06% change from the preceding trading day.
Oscar Health, Inc. (OSCR) Stock Falls Amid Market Uptick: What Investors Need to Know
The latest trading day saw Oscar Health, Inc. (OSCR) settling at $11.60, representing a -0.34% change from its previous close.
Oscar Health, Inc. (OSCR) Stock Drops Despite Market Gains: Important Facts to Note
Oscar Health, Inc. (OSCR) closed at $12.42 in the latest trading session, marking a -1.19% move from the prior day.
Oscar Health, Inc. (OSCR) Increases Despite Market Slip: Here's What You Need to Know
In the most recent trading session, Oscar Health, Inc. (OSCR) closed at $13.61, indicating a +1.8% shift from the previous trading day.
Why Oscar Health, Inc. (OSCR) Outpaced the Stock Market Today
In the closing of the recent trading day, Oscar Health, Inc. (OSCR) stood at $14.19, denoting a +1.65% change from the preceding trading day.
